Latest Immunosuppressants Stories
ResearchMoz.us includes new market research report "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" to its huge collection of research reports.
On June 2, the FDA announced that certain lots of Soliris (eculizumab) Concentrated Solution for IV Infusion, by Alexion, are recalled due to visible particulates.
HORSHOLM, Denmark, June 3, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the hiring of senior level management in preparation for potential U.S.
Leveraging Nurse Support Could Boost Engagement with Rheumatoid Arthritis Brands, According to Findings in New Manhattan Research Analysis from Decision Resources Group BURLINGTON, Mass., June
LifeScienceIndustryResearch.com adds Latest Report on “Frontier Pharma: Psoriasis – Identifying and Commercializing First-in-Class Innovation” to its store. Dallas,
VANCOUVER, May 29, 2014 /PRNewswire/ - Augurex Life Sciences Corp.
HORSHOLM, Denmark, May 22, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile NATICK, Mass., May 21, 2014 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) reported
NORTH CHICAGO, Ill., May 20, 2014 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that the U.S.
AADi Initiates NIH Funded Clinical Trial for Patients with Bladder Cancer PACIFIC PALISADES, Calif., May 20, 2014 /PRNewswire/ -- AADi, LLC, a clinical stage biopharmaceutical company
- totally perplexed and mixed up.